Skip to main content
DongKoo Bio & Pharma Co., Ltd. logo

DongKoo Bio & Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 006620 ISIN · KR7006620009 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2025-03-26 Remuneration Information
Country KR South Korea
Listing KO 006620

About DongKoo Bio & Pharma Co., Ltd.

https://www.dongkoo.com/eng/

DongKoo Bio & Pharma Co., Ltd. is a biopharmaceutical company that manufactures and sells a range of pharmaceuticals and health supplements. The company holds a leading position in the dermatology prescription market, with a product portfolio that includes antihistamines, analgesics, antipyretics, and digestants. Strategically expanding beyond traditional pharmaceuticals, DongKoo Bio & Pharma is focused on the biotechnology sector, particularly the development of stem cell-based therapies. This growth is pursued through an "Open Innovation" model to build a pipeline of differentiated products, supported by its research centers and PIC/s compliant GMP manufacturing facilities.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and equity-based compensation does not fit into specific categories like 10-K or ER, and is best classified as a general regulatory filing (RNS) within the provided schema.
2025-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment and resignation of an outside director (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2025-03-26 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, methods (e.g., open market purchases, off-market trades), and collateral agreements. This document type is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-03-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider transactions (share sales/purchases) by directors or major shareholders. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2025-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Dong-A ST (Dong-A Socio Holdings subsidiary) titled 'Audit Report Submission'. It provides the auditor's opinion (unqualified/proper), key financial data (assets, liabilities, revenue, profit), and confirms the receipt of the audit report. In the context of Korean regulatory filings (DART), this is a standard 'Audit Report Submission' notice, which falls under the 'Audit Report / Information' category as it provides the results of the audit and financial summaries. FY 2024
2025-03-18 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for Dongkoo Bio & Pharma Co., Ltd. for the fiscal year ending December 31, 2024. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This is a formal, full-year financial audit report, which falls under the 'Audit Report / Information' category. FY 2024
2025-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.